What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Gary M. Clark spends much of his time researching Internal medicine, Breast cancer, Oncology, Pathology and Mammary gland.
His study in Endocrinology extends to Internal medicine with its themes.
His biological study spans a wide range of topics, including Immunohistochemistry, Cancer research, Treatment decision making, Neoplasm staging and Oncogene.
His Oncology study combines topics in areas such as Aneuploidy, Survival rate, Disease, Gene duplication and Flow cytometry.
His Mammary gland research is multidisciplinary, incorporating elements of Estrogen and Lymph node.
In his research on the topic of Cancer, Trastuzumab, Neratinib, HER2/Neu Status, HER2/neu and Lapatinib is strongly related with Immunology.
His most cited work include:
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene (9877 citations)
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (3088 citations)
- PROGNOSTIC AND PREDICTIVE FACTORS IN BREAST CANCER BY IMMUNOHISTOCHEMICAL ANALYSIS (1717 citations)
What are the main themes of his work throughout his whole career to date?
Gary M. Clark mainly focuses on Internal medicine, Breast cancer, Oncology, Pathology and Cancer.
His Internal medicine study incorporates themes from Endocrinology and Surgery.
Gary M. Clark combines subjects such as Immunohistochemistry, Cancer research and Estrogen with his study of Breast cancer.
His studies deal with areas such as Proportional hazards model, Disease, Immunology and Survival rate as well as Oncology.
When carried out as part of a general Pathology research project, his work on Carcinoma is frequently linked to work in Context, therefore connecting diverse disciplines of study.
His study on Cancer is mostly dedicated to connecting different topics, such as In vitro.
He most often published in these fields:
- Internal medicine (51.53%)
- Breast cancer (48.47%)
- Oncology (34.69%)
What were the highlights of his more recent work (between 1998-2016)?
- Internal medicine (51.53%)
- Oncology (34.69%)
- Breast cancer (48.47%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Oncology, Breast cancer, Pathology and Cancer.
Internal medicine and Endocrinology are commonly linked in his work.
His Oncology research is multidisciplinary, relying on both Radiation therapy, Incidence, Survival rate, Proportional hazards model and Survival analysis.
His research in Breast cancer intersects with topics in Cancer research, Lymph node and Race.
His work on Carcinoma as part of general Pathology study is frequently connected to Context, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Gary M. Clark interconnects Immunohistochemistry, Axillary lymph nodes and Estrogen in the investigation of issues within Mammary gland.
Between 1998 and 2016, his most popular works were:
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (3088 citations)
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) (1698 citations)
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer (1687 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Breast cancer, Oncology, Pathology and Cancer are his primary areas of study.
His study ties his expertise on Endocrinology together with the subject of Internal medicine.
His Pathology research includes themes of MEDLINE and Intensive care medicine.
His studies examine the connections between Erlotinib and genetics, as well as such issues in Surgery, with regards to General surgery and Lymph node.
His Estrogen receptor study integrates concerns from other disciplines, such as Immunohistochemistry and Estrogen.
The study incorporates disciplines such as Carcinoma, DNA ploidy analysis, Categorical variable and Consensus conference in addition to Mammary gland.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
